Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
608
Shown on this page
8
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 601–608 of 608 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

NCT06160206
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent WHO Grade 4 Glioma
Interventions
Bevacizumab, Biospecimen Collection, Computed Tomography, Electronic Health Record Review, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Retifanlimab
Biological · Procedure · Other + 1 more
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Recruiting Phase 1 Interventional

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

NCT06259552
Status at this site: Recruiting
View directory record Official record
Conditions
Solid Tumor, HNSCC, RCC, CRC
Interventions
SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody
Biological
Lead sponsor
SparX Biotech(Jiangsu) Co., Ltd.
Other
Eligibility
18 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Recruiting Phase 4 Interventional

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping

NCT06385236
Status at this site: Recruiting
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Dupilumab, Benralizumab
Biological
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Scottsdale, Arizona • La Jolla, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Recruiting No phase listed Observational

US National OCS Liver Perfusion (OLP) Registry

NCT05940857
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Transplant
Interventions
OCS Liver
Device
Lead sponsor
TransMedics
Industry
Eligibility
Not listed
Enrollment
100,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
22
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Active, not recruiting No phase listed Observational

Noninterventional Study Evaluating Parkinson's Disease Diary Use

NCT05363046
Site status not listed — check the official record
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
39 Years to 70 Years
Enrollment
194 participants
Timeline
2022 – 2026
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Recruiting Phase 2 Interventional

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

NCT04660760
Status at this site: Recruiting
View directory record Official record
Conditions
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
Interventions
Paclitaxel, Quality-of-Life Assessment, Ramucirumab, Trifluridine and Tipiracil Hydrochloride
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Oct 23, 2026, 2:26 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

NCT03915184
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
zevor-cel
Biological
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2034
U.S. locations
12
States / cities
Phoenix, Arizona • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 23, 2026, 2:26 PM EDT
Active, not recruiting Not applicable Interventional

Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)

NCT03973866
Site status not listed — check the official record
View directory record Official record
Conditions
Ascites
Interventions
Alfapump
Device
Lead sponsor
Sequana Medical N.V.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • Worcester, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 23, 2026, 2:26 PM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.